FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

Antoine Verger; Igor Yakushev; Nathalie L. Albert; Bart van Berckel; Matthias Brendel; Diego Cecchin; Pablo Aguiar Fernandez; Francesco Fraioli; Eric Guedj; Silvia Morbelli; Nelleke Tolboom; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Henryk Barthel

doi:10.1007/s00259-023-06177-5

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

Antoine Verger, Igor Yakushev^*, Nathalie L. Albert, Bart van Berckel, Matthias Brendel, Diego Cecchin, Pablo Aguiar Fernandez, Francesco Fraioli, Eric Guedj, Silvia Morbelli, Nelleke Tolboom, Tatjana Traub-Weidinger, Donatienne Van Weehaeghe, Henryk Barthel

^*Corresponding author for this work

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Downloads (Pure)

Original language	English
Pages (from-to)	1553-1555
Number of pages	3
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	50
Issue number	6
DOIs	https://doi.org/10.1007/s00259-023-06177-5
Publication status	Published - May-2023

Access to Document

10.1007/s00259-023-06177-5Licence: CC BY

FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspectiveFinal publisher's version, 372 KBLicence: CC BY

Handle.net

Persistent link

Cite this

Verger, A., Yakushev, I., Albert, N. L., van Berckel, B., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Guedj, E., Morbelli, S., Tolboom, N., Traub-Weidinger, T., Van Weehaeghe, D., & Barthel, H. (2023). FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective. European Journal of Nuclear Medicine and Molecular Imaging, 50(6), 1553-1555. https://doi.org/10.1007/s00259-023-06177-5

@article{84229ddffdf749dabd3a84ae1e42fb16,

title = "FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective",

author = "Antoine Verger and Igor Yakushev and Albert, {Nathalie L.} and {van Berckel}, Bart and Matthias Brendel and Diego Cecchin and Fernandez, {Pablo Aguiar} and Francesco Fraioli and Eric Guedj and Silvia Morbelli and Nelleke Tolboom and Tatjana Traub-Weidinger and {Van Weehaeghe}, Donatienne and Henryk Barthel",

year = "2023",

month = may,

doi = "10.1007/s00259-023-06177-5",

language = "English",

volume = "50",

pages = "1553--1555",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "SPRINGER",

number = "6",

}

Verger, A, Yakushev, I, Albert, NL, van Berckel, B, Brendel, M, Cecchin, D, Fernandez, PA, Fraioli, F, Guedj, E, Morbelli, S, Tolboom, N, Traub-Weidinger, T, Van Weehaeghe, D & Barthel, H 2023, 'FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 6, pp. 1553-1555. https://doi.org/10.1007/s00259-023-06177-5

TY - JOUR

T1 - FDA approval of lecanemab

T2 - the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective

AU - Verger, Antoine

AU - Yakushev, Igor

AU - Albert, Nathalie L.

AU - van Berckel, Bart

AU - Brendel, Matthias

AU - Cecchin, Diego

AU - Fernandez, Pablo Aguiar

AU - Fraioli, Francesco

AU - Guedj, Eric

AU - Morbelli, Silvia

AU - Tolboom, Nelleke

AU - Traub-Weidinger, Tatjana

AU - Van Weehaeghe, Donatienne

AU - Barthel, Henryk

PY - 2023/5

Y1 - 2023/5

U2 - 10.1007/s00259-023-06177-5

DO - 10.1007/s00259-023-06177-5

M3 - Editorial

C2 - 36869178

AN - SCOPUS:85149212696

SN - 1619-7070

VL - 50

SP - 1553

EP - 1555

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -